Long-term outcomes of polycythemia vera patients treated with ropeginterferon Alfa-2b

被引：79

作者：

Kiladjian, Jean-Jacques ^{[1
]}

Klade, Christoph ^{[2
]}

Georgiev, Pencho ^{[3
]}

Krochmalczyk, Dorota ^{[4
]}

Gercheva-Kyuchukova, Liana ^{[5
]}

Egyed, Miklos ^{[6
]}

Dulicek, Petr ^{[7
]}

Illes, Arpad ^{[8
]}

Pylypenko, Halyna ^{[9
]}

Sivcheva, Lylia ^{[10
]}

Mayer, Jiri ^{[11
]}

Yablokova, Vera ^{[12
]}

Krejcy, Kurt ^{[2
]}

Empson, Victoria ^{[2
]}

Hasselbalch, Hans C. ^{[13
,14
]}

Kralovics, Robert ^{[15
,16
]}

Gisslinger, Heinz ^{[17
]}

机构：

[1] Univ Paris, Hop St Louis, AP HP, Ctr Invest Clin,INSERM,CIC1427, Paris, France

[2] AOP Orphan Pharmaceut, Vienna, Austria

[3] Med Univ Plovdiv, Plovdiv, Bulgaria

[4] Univ Hosp Krakow, Teaching Unit, Dept Hematol, Krakow, Poland

[5] Multiprofile Hosp Act Treatment Sveta Marina, Clin Hematol Clin, Varna, Bulgaria

[6] Kaposi Mor Cty Teaching Hosp, Dept Internal Med 2, Kaposvar, Hungary

[7] Univ Hosp Hradec Kralove, Dept Clin Hematol, Hradec Kralove, Czech Republic

[8] Univ Debrecen, Fac Med, Dept Hematol, Debrecen, Hungary

[9] Cherkasy Reg Oncol Ctr, Reg Treatment & Diagnost Hematol Ctr, Dept Hematol, Cherkassy, Ukraine

[10] Multiprofile Hosp Act Treatment HristoBotev, Dept Internal Med 1, Vratsa, Bulgaria

[11] Univ Hosp Brno, Clin Internal Med Hematol & Oncol, Brno, Czech Republic

[12] Yaroslavl Reg Clin Hosp, Dept Hematol, Yaroslavl, Russia

[13] Zealand Univ Hosp, Dept Hematol, Roskilde, Denmark

[14] Univ Copenhagen, Copenhagen, Denmark

[15] Med Univ Vienna, Dept Lab Med, Vienna, Austria

[16] Austrian Acad Sci, CeMM Res Ctr Mol Med, Vienna, Austria

[17] Med Univ Vienna, Dept Internal Med 1, Div Hematol & Blood Coagulat, Vienna, Austria

来源：

LEUKEMIA | 2022年 / 36卷 / 05期

关键词：

ESSENTIAL THROMBOCYTHEMIA; LOW TOXICITY; TRANSFORMATION;

D O I：

10.1038/s41375-022-01528-x

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

[No abstract available]

引用

页码：1408 / 1411

页数：4

共 15 条

[1] Interferon-alpha for treating polycythemia vera yields improved myelofibrosis-free and overall survival [J].

Abu-Zeinah, Ghaith ;

Krichevsky, Spencer ;

Cruz, Tatiana ;

Hoberman, Gabriela ;

Jaber, Diana ;

Savage, Niamh ;

Sosner, Claudia ;

Ritchie, Ellen K. ;

Scandura, Joseph M. ;

Silver, Richard T. .

LEUKEMIA, 2021, 35 (09) :2592-2601

[2] JAK2V617F monitoring in polycythemia vera and essential thrombocythemia: Clinical usefulness for predicting myelofibrotic transformation and thrombotic events [J].

Alvarez-Larran, Alberto ;

Bellosillo, Beatriz ;

Pereira, Arturo ;

Kerguelen, Ana ;

Carlos Hernandez-Boluda, Juan ;

Martinez-Aviles, Luz ;

Fernandez-Rodriguez, Concepcion ;

Gomez, Montse ;

Lombardia, Luis ;

Angona, Anna ;

Ancochea, Agueda ;

Senin, Alicia ;

Longaron, Raquel ;

Navarro, Blanca ;

Collado, Maria ;

Besses, Carlos .

AMERICAN JOURNAL OF HEMATOLOGY, 2014, 89 (05) :517-523

[3] Response criteria for essential thrombocythemia and polycythemia vera: result of a European LeukemiaNet consensus conference [J].

Barosi, Giovanni ;

Birgegard, Gunnar ;

Finazzi, Guido ;

Griesshammer, Martin ;

Harrison, Claire ;

Hasselbalch, Hans Carl ;

Kiladjian, Jean-Jacques ;

Lengfelder, Eva ;

McMullin, Mary Frances ;

Passamonti, Francesco ;

Reilly, John T. ;

Vannucchi, Alessandro M. ;

Barbui, Tiziano .

BLOOD, 2009, 113 (20) :4829-4833

[4] Interferon-Alpha (IFN) Therapy Discontinuation Is Feasible in Myeloproliferative Neoplasm (MPN) Patients with Complete Hematological Remission [J].

De Oliveira, Rafael Daltro ;

Soret-Dulphy, Juliette ;

Zhao, Lin-Pierre ;

Marcault, Clemence ;

Gauthier, Nicolas ;

Verger, Emmanuelle ;

Maslah, Nabih ;

Parquet, Nathalie ;

Raffoux, Emmanuel ;

Vainchenker, William ;

Chomienne, Christine ;

Cassinat, Bruno ;

Benajiba, Lina ;

Kiladjian, Jean-Jacques .

BLOOD, 2020, 136

[5] Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and CONTINUATION-PV): a randomised, non-inferiority, phase 3 trial and its extension study [J].

Gisslinger, Heinz ;

Klade, Christoph ;

Georgiev, Pencho ;

Krochmalczyk, Dorota ;

Gercheva-Kyuchukova, Liana ;

Egyed, Miklos ;

Rossiev, Viktor ;

Dulicek, Petr ;

Illes, Arpad ;

Pylypenko, Halyna ;

Sivcheva, Lylia ;

Mayer, Jiri ;

Yablokova, Vera ;

Krejcy, Kurt ;

Grohmann-Izay, Barbara ;

Hasselbalch, Hans C. ;

Kralovics, Robert ;

Kiladjian, Jean-Jacques .

LANCET HAEMATOLOGY, 2020, 7 (03) :E196-E208

[6] Ropeginterferon alfa-2b, a novel IFNα-2b, induces high response rates with low toxicity in patients with polycythemia vera [J].

Gisslinger, Heinz ;

Zagrijtschuk, Oleh ;

Buxhofer-Ausch, Veronika ;

Thaler, Josef ;

Schloegl, Ernst ;

Gastl, Guenther A. ;

Wolf, Dominik ;

Kralovics, Robert ;

Gisslinger, Bettina ;

Strecker, Karin ;

Egle, Alexander ;

Melchardt, Thomas ;

Burgstaller, Sonja ;

Willenbacher, Ella ;

Schalling, Martin ;

Them, Nicole C. ;

Kadlecova, Pavla ;

Klade, Christoph ;

Greil, Richard .

BLOOD, 2015, 126 (15) :1762-1769

[7] Perspectives on interferon-alpha in the treatment of polycythemia vera and related myeloproliferative neoplasms: minimal residual disease and cure? [J].

Hasselbalch, Hans Carl ;

Holmstroem, Morten Orebo .

SEMINARS IN IMMUNOPATHOLOGY, 2019, 41 (01) :5-19

[8] The roles of JAK2 in DNA damage and repair in the myeloproliferative neoplasms: Opportunities for targeted therapy [J].

Karantanos, Theodoros ;

Moliterno, Alison R. .

BLOOD REVIEWS, 2018, 32 (05) :426-432

[9] Interferon-alpha for the therapy of myeloproliferative neoplasms: targeting the malignant clone [J].

Kiladjian, J-J ;

Giraudier, S. ;

Cassinat, B. .

LEUKEMIA, 2016, 30 (04) :776-781

[10] Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera [J].

Kiladjian, Jean-Jacques ;

Cassinat, Bruno ;

Chevret, Sylvie ;

Turlure, Pascal ;

Cambier, Nathalie ;

Roussel, Murielle ;

Bellucci, Sylvia ;

Grandchamp, Bernard ;

Chomienne, Christine ;

Fenaux, Pierre .

BLOOD, 2008, 112 (08) :3065-3072

← 1 2 →